Details for Patent: 8,772,315
✉ Email this page to a colleague
Which drugs does patent 8,772,315 protect, and when does it expire?
Patent 8,772,315 protects MYRBETRIQ and is included in one NDA.
Protection for MYRBETRIQ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twelve patent family members in eleven countries.
Summary for Patent: 8,772,315
| Title: | Pharmaceutical composition for treating overactive bladder |
| Abstract: | A pharmaceutical composition comprising (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}a- cetanilide or a pharmaceutically acceptable salt thereof and (3R)-quinuclidin-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a pharmaceutically acceptable salt thereof, as active ingredients, in particular for improving various symptoms accompanying overactive bladder, such as urinary urgency, pollakiuria and/or urinary incontinence. |
| Inventor(s): | Suzuki; Masanori (Chuo-ku, JP), Ukai; Masashi (Chuo-ku, JP), Ohtake; Akiyoshi (Chuo-ku, JP) |
| Assignee: | Astellas Pharma Inc. (Tokyo, JP) |
| Application Number: | 13/748,956 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,772,315 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Delivery; |
Drugs Protected by US Patent 8,772,315
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,772,315
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | P2007-285802 | Nov 2, 2007 |
International Family Members for US Patent 8,772,315
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2704298 | ⤷ Sign Up | |||
| Cyprus | 1113670 | ⤷ Sign Up | |||
| Denmark | 2216021 | ⤷ Sign Up | |||
| European Patent Office | 2216021 | ⤷ Sign Up | |||
| Spain | 2393525 | ⤷ Sign Up | |||
| Croatia | P20121078 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
